GANX Strangle Strategy
GANX (Gain Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
GANX (Gain Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $75.9M, a beta of 0.15 versus the broader market, a 52-week range of 1.41-4.34, average daily share volume of 684K, a public-listing history dating back to 2021, approximately 23 full-time employees. These structural characteristics shape how GANX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.15 indicates GANX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on GANX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current GANX snapshot
As of May 15, 2026, spot at $1.77, ATM IV 198.10%, IV rank 44.88%, expected move 56.79%. The strangle on GANX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on GANX specifically: GANX IV at 198.10% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 56.79% (roughly $1.01 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GANX expiries trade a higher absolute premium for lower per-day decay. Position sizing on GANX should anchor to the underlying notional of $1.77 per share and to the trader's directional view on GANX stock.
GANX strangle setup
The GANX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GANX near $1.77, the first option leg uses a $1.86 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GANX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GANX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.86 | N/A |
| Buy 1 | Put | $1.68 | N/A |
GANX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
GANX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on GANX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on GANX
Strangles on GANX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GANX chain.
GANX thesis for this strangle
The market-implied 1-standard-deviation range for GANX extends from approximately $0.76 on the downside to $2.78 on the upside. A GANX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GANX IV rank near 44.88% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on GANX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, GANX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GANX-specific events.
GANX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GANX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GANX alongside the broader basket even when GANX-specific fundamentals are unchanged. Always rebuild the position from current GANX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on GANX?
- A strangle on GANX is the strangle strategy applied to GANX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GANX stock trading near $1.77, the strikes shown on this page are snapped to the nearest listed GANX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are GANX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GANX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 198.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a GANX strangle?
- The breakeven for the GANX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GANX market-implied 1-standard-deviation expected move is approximately 56.79%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on GANX?
- Strangles on GANX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GANX chain.
- How does current GANX implied volatility affect this strangle?
- GANX ATM IV is at 198.10% with IV rank near 44.88%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.